Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.
about
Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alphaPrognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospectsA Novel Unsupervised Method to Identify Genes Important in the Anti-viral Response: Application to Interferon/Ribavirin in Hepatitis C PatientsDifferential expression of viral PAMP receptors mRNA in peripheral blood of patients with chronic hepatitis C infectionInterferon signaling and treatment outcome in chronic hepatitis CHepatitis C and Innate Immunity: Recent AdvancesPeginterferon Pharmacokinetics in African American and Caucasian American Patients With Hepatitis C Virus Genotype 1 InfectionMechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.Gene network reconstruction reveals cell cycle and antiviral genes as major drivers of cervical cancerAnalysis of time-resolved gene expression measurements across individualsChIP-PED enhances the analysis of ChIP-seq and ChIP-chip dataHepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.Gene transcript abundance profiles distinguish Kawasaki disease from adenovirus infectionCell subset prediction for blood genomic studiesIn vitro blood cell responsiveness to IFN-α predicts clinical response independently of IL28B in hepatitis C virus genotype 1 infected patients.Ribavirin improves early responses to peginterferon through improved interferon signalingThe induction of type I interferon production in hepatitis C-infected patients.A derived network-based interferon-related signature of human macrophages responding to Mycobacterium tuberculosisPredicting the probable outcome of treatment in HCV patients.S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment responseIL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection.Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments.Defective response to Toll-like receptor 3 and 4 ligands by activated monocytes in chronic hepatitis C virus infection.Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis CHost gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a.Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC).Transcriptional Dysregulation of Upstream Signaling of IFN Pathway in Chronic HCV Type 4 Induced Liver Fibrosis.Large-scale gene co-expression network as a source of functional annotation for cattle genesT-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection.Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture modelsThe blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response.The prediction of interferon treatment effects based on time series microarray gene expression profiles.Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes.Focal gains of VEGFA and molecular classification of hepatocellular carcinomaCyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment.Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.Trisomy 21 consistently activates the interferon response.
P2860
Q21245110-57CFC179-4421-4932-A95D-81628C54F261Q27021265-5363220F-0B40-436B-9A34-4D141B166035Q27481065-8DB4B91B-A3E5-4F9B-BB00-3495ABDC0F04Q27485133-5550AA50-BCBE-4C0D-A73D-B33FB9492A6DQ27486083-B6684959-3F5A-4DCA-9067-54F6A5BB1F98Q27487394-60E145C3-857B-4DFE-A965-7FFFCA97EBE3Q27488869-8B9012EB-6A7F-4914-8D5B-5391AC21EDC5Q27490650-8579DAD2-0434-4703-A624-9E318C61B3B3Q28119171-77FA2107-06FE-47F5-94FC-5D8BF32D90F3Q28536632-200C2125-A85A-4AFD-9F21-30E09D6A9EB0Q30596570-83F092C4-D83D-4921-A8B8-460AD6C0B2D1Q33597579-0728286E-662B-475E-B2C0-0773F78D6EA4Q33816657-007EB901-FD09-4A13-953D-5FA5ED7650E7Q33883840-F44517AD-C591-4BE1-A946-6F77BBA2052EQ33942400-35C73320-FFDB-4384-AED2-CEB4B9126D9AQ33958609-FAA04E66-C637-48A9-9CD2-4A9B061688B4Q33987120-5FB32C33-5D26-4DB4-900D-53A5B53E3510Q34208032-6FA1EFB7-B5EA-49E1-A01F-8D117392755CQ34406300-2B463AEA-0E96-4BB8-AF2B-C82B6B120221Q34409039-C38D383B-9DB3-4718-A472-31ED7C1043D7Q34493348-7E88909C-FEFA-4F4E-B19B-1E56AB06AA2BQ34593704-E9E6CEB7-A797-4431-BB74-47337250226FQ34867045-ECB7E55F-1536-4156-AC57-D833C63626E3Q35042843-C42FECB7-9C8E-403E-AA30-A78DF001DA77Q35047686-A8958CE1-6C6F-4B41-BBB1-9EF7B4B0F2DCQ35056266-7A7E1D6B-EA3E-494D-B374-385B76DADD4AQ35508148-3776000C-B494-4B59-AFBD-C3681C96521DQ35883429-DB7796D6-4355-490A-A0EF-09E5B35C68F0Q35927750-A687C8ED-A370-4999-8801-B4C2624731D1Q36004897-7105BF92-E80E-4EB8-BB12-7A31DA8FBA27Q36180621-AFDF8B19-3839-4863-B61F-04BE90AFA19CQ36215165-D86EDD8B-E165-40DD-A695-082B17475650Q36399860-D59212CB-EBBF-40E2-8504-DE4CD1CEE8A7Q36515443-A5983498-15AA-4899-8636-D7A0777FCFCDQ36897181-DAE0C0E5-A5CE-4083-B2AD-3F668F4512F3Q36960285-5888C03B-469E-49B9-9C7E-35DF96D0946EQ36984575-B0E18852-5A85-4E6C-AE96-C1D1F3CAE987Q37037077-66A05CFF-93B4-41C6-A128-463F17D559FCQ37185209-34F9CEAB-01D7-48CD-B57C-0B145A83EF91Q37235217-2C4430E8-A9B6-4FD8-9105-08184455C5E2
P2860
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Changes in gene expression dur ...... sponders to antiviral therapy.
@ast
Changes in gene expression dur ...... sponders to antiviral therapy.
@en
type
label
Changes in gene expression dur ...... sponders to antiviral therapy.
@ast
Changes in gene expression dur ...... sponders to antiviral therapy.
@en
prefLabel
Changes in gene expression dur ...... sponders to antiviral therapy.
@ast
Changes in gene expression dur ...... sponders to antiviral therapy.
@en
P2093
P2860
P356
P1433
P1476
Changes in gene expression dur ...... sponders to antiviral therapy.
@en
P2093
Charles Howell
Corneliu Sanda
Joel Schaley
John E Tavis
Leonid Brodsky
Matthew J Stephens
Milton W Taylor
Steven H Belle
Takuma Tsukahara
P2860
P304
P356
10.1128/JVI.02640-06
P407
P577
2007-01-31T00:00:00Z